Clinical characteristics and treatment of elderly onset adult-onset Still’s disease

被引:0
|
作者
Dai Kishida
Takanori Ichikawa
Ryota Takamatsu
Shun Nomura
Masayuki Matsuda
Wataru Ishii
Tatsuo Nagai
Sadahiro Suzuki
Ken-ichi Ueno
Naoki Tachibana
Yasuhiro Shimojima
Yoshiki Sekijima
机构
[1] Shinshu University School of Medicine,Department of Medicine (Neurology and Rheumatology)
[2] Saku Central Hospital,Department of Rheumatology
[3] Nagano Red Cross Hospital,Division of Rheumatology, Department of Internal Medicine
[4] Minaminagano Medical Center,Department of Rheumatology
[5] Shinonoi General Hospital,Department of Rheumatology
[6] Japanese Red Cross Society Suwa Hospital,Department of Nephrology
[7] Japanese Red Cross Society Suwa Hospital,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Adult-onset Still’s disease (AOSD)—a systemic inflammatory disease—often occurs at a young age. Recently, elderly onset patient proportion has been increasing; however, data are limited. To evaluate the characteristics of elderly patients with AOSD in a multicenter cohort, we retrospectively analyzed 62 patients with AOSD at five hospitals during April 2008–December 2020. Patients were divided into two groups according to age at disease onset: younger-onset (≤ 64 years) and elderly onset (≥ 65 years). Clinical symptoms, complications, laboratory findings, treatment, and outcomes were compared. Twenty-six (41.9%) patients developed AOSD at age ≥ 65 years. The elderly onset group had a lower frequency of sore throat (53.8% vs. 86.1%), higher frequency of pleuritis (46.2% vs. 16.7%), and higher complication rates of disseminated intravascular coagulation (30.8% vs. 8.3%) and macrophage activation syndrome (19.2% vs. 2.8%) than the younger onset group. Cytomegalovirus infections were frequent in elderly onset patients (38.5% vs. 13.9%) but decreased with early glucocorticoid dose reduction and increased immunosuppressant and tocilizumab use. Elderly AOSD is not uncommon; these patients have different characteristics than younger-onset patients. Devising a way to control disease activity quickly while managing infections may be an important goal in elderly AOSD.
引用
收藏
相关论文
共 50 条
  • [21] Adult-onset Still’s disease
    Valentina Bagnari
    Matteo Colina
    Giovanni Ciancio
    Marcello Govoni
    Francesco Trotta
    Rheumatology International, 2010, 30 : 855 - 862
  • [22] Adult-onset Still's disease
    Bagnari, Valentina
    Colina, Matteo
    Ciancio, Giovanni
    Govoni, Marcello
    Trotta, Francesco
    RHEUMATOLOGY INTERNATIONAL, 2010, 30 (07) : CP9 - 862
  • [23] Adult-onset Still's disease
    Gerfaud-Valentin, Mathieu
    Jamilloux, Yvan
    Iwaz, Jean
    Seve, Pascal
    AUTOIMMUNITY REVIEWS, 2014, 13 (07) : 708 - 722
  • [24] Adult-onset Still's disease
    Kádár, J
    Petrovicz, E
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2004, 18 (05): : 663 - 676
  • [25] Clinical characteristics, treatment and outcome of adult-onset Still's disease in Southern Chinese.
    Mok, CC
    Lau, CS
    Wong, RWS
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S232 - S232
  • [26] Clinical characteristics of macrophage activation syndrome in adult-onset Still's disease
    Gao, Q.
    Yuan, Y.
    Wang, Y.
    Jiang, J.
    Ye, Z.
    Liu, T.
    Jiang, Z.
    Zhao, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : S59 - S66
  • [27] Adolescent-onset Still's disease: Characteristics and outcome in comparison with adult-onset Still's disease
    Luthi, F
    Zufferey, P
    Hofer, MF
    So, AK
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (03) : 427 - 430
  • [28] Adult-onset Still's disease with elderly onset: results from a multicentre study
    Di Cola, I.
    Di Muzio, C.
    Conforti, A.
    Iacono, D.
    Pantano, I.
    Rozza, G.
    Rossi, S.
    De Stefano, L.
    Vitale, A.
    Caso, F.
    Costa, L.
    Prete, M.
    Navarini, L.
    Iagnocco, A.
    Atzeni, F.
    Guggino, G.
    Perosa, F.
    Cantarini, L.
    Frediani, B.
    Bugatti, S.
    Montecucco, C.
    Ciccia, F.
    Giacomelli, R.
    Cipriani, P.
    Ruscitti, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (08) : 1517 - 1525
  • [29] Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence
    Hubert de Boysson
    Jérome Février
    Amélie Nicolle
    Christophe Auzary
    Loïk Geffray
    Clinical Rheumatology, 2013, 32 : 141 - 147
  • [30] Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence
    de Boysson, Hubert
    Fevrier, Jerome
    Nicolle, Amelie
    Auzary, Christophe
    Geffray, Loik
    CLINICAL RHEUMATOLOGY, 2013, 32 (01) : 141 - 147